Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Arnst

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Zentralblatt Fur Arbeitsmedizin, Arbeitsschutz, Prophylaxe Und Ergonomie|January 1, 1980
[Long-term serum enzyme activities]C D Koch, E Arnst, K Rommel
Das Medizinische Laboratorium|January 1, 1980
[Interpretation of serum protein data: individual normal values or reference areas?]C D Koch, E Arnst, K Rommel
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie|July 1, 1980
[Urea and creatinine levels and clearances: observations in 25 healthy subjects for one year (author's transl)]C D Koch, E Arnst, K Rommel
Molecules (Basel, Switzerland)|August 2, 2017
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer TherapyHao Chen, Zongtao Lin, Kinsie E Arnst, et al.
Medicinal Research Reviews|February 13, 2019
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapyKinsie E Arnst, Souvik Banerjee, Hao Chen, et al.
European Journal of Medicinal Chemistry|March 5, 2018
Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitorsQinghui Wang, Kinsie E Arnst, Yi Xue, et al.
ACS Chemical Biology|November 13, 2019
X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization InhibitorsKinsie E Arnst, Souvik Banerjee, Yuxi Wang, et al.
Biochemical and Biophysical Research Communications|February 23, 2020
Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug designTao Wang, Chengyong Wu, Chengdi Wang, et al.
Journal of Medicinal Chemistry|June 29, 2019
Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1<i>H</i>-Indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in TubulinQinghui Wang, Kinsie E Arnst, Yuxi Wang, et al.
Journal of Medicinal Chemistry|August 21, 2018
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative ActivitiesQinghui Wang, Kinsie E Arnst, Yuxi Wang, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Zentralblatt Fur Arbeitsmedizin, Arbeitsschutz, Prophylaxe Und Ergonomie|January 1, 1980
[Long-term serum enzyme activities]C D Koch, E Arnst, K Rommel
Das Medizinische Laboratorium|January 1, 1980
[Interpretation of serum protein data: individual normal values or reference areas?]C D Koch, E Arnst, K Rommel
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie|July 1, 1980
[Urea and creatinine levels and clearances: observations in 25 healthy subjects for one year (author's transl)]C D Koch, E Arnst, K Rommel
Molecules (Basel, Switzerland)|August 2, 2017
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer TherapyHao Chen, Zongtao Lin, Kinsie E Arnst, et al.
Medicinal Research Reviews|February 13, 2019
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapyKinsie E Arnst, Souvik Banerjee, Hao Chen, et al.
European Journal of Medicinal Chemistry|March 5, 2018
Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitorsQinghui Wang, Kinsie E Arnst, Yi Xue, et al.
ACS Chemical Biology|November 13, 2019
X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization InhibitorsKinsie E Arnst, Souvik Banerjee, Yuxi Wang, et al.
Biochemical and Biophysical Research Communications|February 23, 2020
Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug designTao Wang, Chengyong Wu, Chengdi Wang, et al.
Journal of Medicinal Chemistry|June 29, 2019
Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1<i>H</i>-Indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in TubulinQinghui Wang, Kinsie E Arnst, Yuxi Wang, et al.
Journal of Medicinal Chemistry|August 21, 2018
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative ActivitiesQinghui Wang, Kinsie E Arnst, Yuxi Wang, et al.
Pageof 2